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Abstract
NADH:ubiquinone oxidoreductase (complex I) is the first, largest and most complicated enzyme of the mitochondrial
electron transport chain. Photoaffinity labeling with the highly potent and specific inhibitor trifluoromethyldiazirinyl-
[3H]pyridaben ([3H]TDP) labels only the PSST and ND1 subunits of complex I in electron transport particles. PSST is
labeled at a high-affinity site responsible for inhibition of enzymatic activity while ND1 is labeled at a low-affinity site not
related to enzyme inhibition. In this study we found, as expected, that 13 complex I inhibitors decreased labeling at the PSST
site without effect on ND1 labeling. However, there were striking exceptions where an apparent interaction was found
between the PSST and ND1 subunits : preincubation with NADH increases PSST labeling and decreases ND1 labeling; the
very weak complex I inhibitor 1-methyl-4-phenylpyridinium ion (MPP) and the semiquinone analogue stigmatellin show
the opposite effect with increased labeling at ND1 coupled to decreased labeling at PSST in a concentration- and time-
dependent manner. MPP, stigmatellin and ubisemiquinone have similarly positioned centers of highly negative and positive
electrostatic potential surfaces. Perhaps the common action of MPP and stigmatellin on the functional coupling of the PSST
and ND1 subunits is initiated by binding at a semiquinone binding site in complex I. ß 2001 Elsevier Science B.V. All
rights reserved.
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1. Introduction
NADH:ubiquinone oxidoreductase (complex I),
the ¢rst and most complicated enzyme of the electron
transport chain, consists of 42 or 43 subunits [1],
seven of which are encoded in the mitochondrial ge-
nome and the remainder originate from nuclear
DNA [2]. These subunits catalyze the transfer of elec-
trons from NADH to ubiquinone through £avin
mononucleotide and at least ¢ve iron^sulfur clusters
[2]. The catalytic core of complex I may be regarded
as the PSST, TYKY, 49 kDa, ND1 and ND5 sub-
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units [3]. The PSST subunit is proposed to couple
electron transfer from iron^sulfur cluster N2 to ubi-
quinone [4] and ND1 is a candidate subunit to house
a ubiquinone binding site [5]. The three-dimensional
structure of complex I has been determined only at
low resolution [6]. Alternative approaches are neces-
sary to establish the functional relationship between
subunits. One of these is photoa⁄nity labeling in
which a potent inhibitor of electron transport is al-
lowed to bind at its high-a⁄nity site where, on ex-
posure to light, it covalently derivatizes the site (e.g.
subunit) for characterization.
A serendipitous discovery was made during our
studies on photoa⁄nity labeling of electron transport
particles (ETP) with the potent complex I inhibitor
tri£uoromethyldiazirinyl-[3H]pyridaben ([3H]TDP)
(Fig. 1). The [3H]TDP high-a⁄nity labeling site was
conclusively identi¢ed as being on the PSST subunit
and fully accounting for inhibition of enzymatic ac-
tivity [4]. However, [3H]TDP also labeled a low-af-
¢nity site, unrelated to NADH oxidase activity, lo-
calized on ND1. [3H]TDP was therefore a potential
probe to establish the functional relationship be-
tween PSST and ND1. Other complex I inhibitors
were accordingly examined with the expected ¢nding
that most of them inhibited [3H]TDP labeling of
PSST but not ND1. Surprisingly, two respiratory
chain inhibitors a¡ected both PSST and ND1, de-
creasing the labeling of PSST but increasing that of
ND1 in an apparently coupled manner. These excep-
tions were 1-methyl-4-phenylpyridinium ion (MPP)
(a very weak complex I inhibitor which induces a
parkinsonian syndrome [7]) and stigmatellin (a very
potent complex III inhibitor and moderately potent
complex I inhibitor [8]) with no obvious structural
feature in common with the classical complex I in-
hibitors, e.g. rotenone (Fig. 1). NADH was used to
facilitate [3H]TDP binding but unexpectedly in-
creased PSST labeling while decreasing ND1 label-
ing. This report describes the serendipitous observa-
tion of dual and opposing e¡ects on PSST and ND1
and implications on functional coupling between
these subunits.
2. Materials and methods
2.1. Materials
ETP were prepared by a described procedure [9].
Protein was determined with the bicinchoninic acid
assay (Pierce, Rockford, IL, USA). L-Lactate dehy-
drogenase (LDH) (type XXXIX, from rabbit muscle)
and decylubiquinone (DB) were from Sigma (St.
Louis, MO, USA). All inhibitors used were also
from Sigma or were available from earlier studies
[4,10] except for stigmatellin from Fluka (St. Louis,
MO, USA), thiangazole from Syngenta (Basel, Swit-
zerland), tebufenpyrad from American Cyanamid
(Parsippany, NJ, USA) and fenpyroximate from Ni-
hon Nohyaku (Osaka, Japan). Synthesis of [3H]TDP
(56 Ci/mmol) is described by Latli et al. [11]. MPP
was prepared by N-methylation of 4-phenylpyridine
with excess iodomethane [12] in acetonitrile and re-
crystallized from ethanol to a purity of s 95%.
2.2. Enzyme activity assays
Inhibition of NADH:ubiquinone oxidoreductase
was determined by the NADH oxidase and NADH:
quinone reductase assays [13]. For the NADH oxi-
dase assay, ETP (20 Wg protein) were incubated with
Fig. 1. Main inhibitors used in this study. Tri£uoromethyldia-
zirinyl-[3H]pyridaben (a) is an outstanding photoa⁄nity probe
because it combines exceptional potency as a NADH:ubiqui-
none oxidoreductase inhibitor (IC50 2.4 nM in the NADH oxi-
dase assay), high speci¢c activity (56 Ci/mmol) and suitable
photoreactivity (t1=2 = 6 min under the irradiation conditions
used). Rotenone (b), stigmatellin (c) (in which R is a long, un-
saturated side chain), MPP (d) and others were used here as
inhibitors competing with the binding of (a).
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the inhibitor in 990 Wl bu¡er (250 mM sucrose, 50
mM sodium phosphate, pH 7.5) for 5 min at 30‡C.
Residual activity was determined by addition of
NADH (200 WM ¢nal concentration) in 0.1% sodium
bicarbonate (10 Wl) and monitoring for 2 min at 340
nm. The NADH oxidase procedure was varied in all
studies with MPP as follows: ETP (100 Wg protein)
incubated with MPP (0^20 mM) in 1 ml bu¡er for
5^100 min at 25‡C, then NADH added (400 WM ¢nal
concentration) with monitoring for 1 min at 340 nm.
Each assay was performed in triplicate; the control
activity of the ETP preparation used was 2.3 þ 0.1
Wmol NADH/min/mg ETP at 30‡C. The NADH:qui-
none reductase assay was performed using ETP (40
Wg protein) incubated with the inhibitor (0^20 mM)
and NADH (200 WM) in 990 Wl bu¡er as above con-
taining 2 mM potassium cyanide and 2 WM antimy-
cin A for 5^30 min at 30‡C. The assay was started by
addition of DB (100 WM ¢nal concentration) in etha-
nol (10 Wl) and monitored for 2 min at 340 nm; the
control activity for this assay was 0.53 þ 0.05 Wmol
NADH/min/mg ETP. IC50 values (molar concentra-
tions for 50% inhibition) were determined by itera-
tive nonlinear least-square regression using the Sig-
maPlot software (SPSS, Chicago, IL, USA).
2.3. Photoa⁄nity labeling
ETP (300 Wg protein) were incubated with the in-
hibitor in bu¡er (3 ml) as above. Next, [3H]TDP (8^
100 nM ¢nal concentration) was added in ethanol
(10 Wl) followed by incubation for 5^100 min.
Then, NADH or NAD (400 WM ¢nal concentration),
DB (0 or 30 WM, added in 10 Wl ethanol) and sodium
pyruvate (1 mM ¢nal concentration, introduced in
bu¡er) were added and incubated for 10 min at
25‡C. Immediately before photochemical activation
of [3H]TDP, residual NADH (O340max = 6.22 mM
31
cm31) was oxidized using LDH (3 units) so that it
would not quench the UV light and thereby prevent
photoa⁄nity labeling. Samples were then irradiated
for 30 min at 10‡C in a Rayonet photochemical re-
actor equipped with a merry-go-round apparatus and
six RPR-3500A lamps. Proteins were pelleted (12
min, 144 000Ug, 4‡C) for analysis by 13.5% sodium
dodecyl sulfate^polyacrylamide gel electrophoresis
(SDS^PAGE), cutting in 2 mm slices and liquid scin-
tillation counting as previously described [4]. Fluoro-
graphic analysis of 3H-labeled proteins separated by
SDS^PAGE was performed with Amplify on Hyper-
¢lm MP (Amersham Pharmacia Biotech, Piscataway,
NJ, USA) according to the manufacturer’s instruc-
tions.
Signi¢cant di¡erences among the groups were de-
termined by one-way analysis of variance followed
by Bonferroni’s method.
2.4. Molecular modeling
Density functional calculations based on Becke-
Perdew (referred to as BP86) [14] were made for
analogues of stigmatellin and ubisemiquinone (meth-
yl replacing the long unsaturated side chain) and for
MPP on the DN** basis set. The electrostatic po-
tential surfaces were then generated by mapping the
density functionals onto electron density surfaces
(0.002 electron/Aî ) using the program SPARTAN
(Spartan 5.1, Wavefunction, Irvine, CA, USA).
3. Results
3.1. E¡ects of NADH and decylubiquinone on
[3H]TDP labeling of PSST and ND1
The e¡ects were examined of NADH, NAD and
DB on [3H]TDP labeling of the two subunits (Fig. 2).
The [3H]TDP level used (80 nM) gave similar label-
ing of PSST and ND1 in the controls with no cofac-
tor or substrate. The basal levels of PSST and ND1
labeling were una¡ected or not greatly changed by
NAD or DB alone or together. In contrast, NADH
increased PSST labeling and decreased ND1 labeling
signi¢cantly (Fig. 2) with no apparent e¡ect of DB
on this labeling.
3.2. E¡ects of respiratory chain inhibitors on
NADH:quinone reductase activity and on
[3H]TDP labeling of PSST and ND1
Seventeen compounds were examined for inhibi-
tory e¡ects on enzyme activity and [3H]TDP labeling
of PSST and ND1 (Table 1). All of the compounds
are primarily complex I inhibitors except myxothia-
zol and stigmatellin, which are more potent on com-
plex III than I, and antimycin A which is only a
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complex III inhibitor. Nine potent complex I inhib-
itors (including rotenone, piericidin A and bullata-
cin) at 2 WM almost completely block PSST labeling
without greatly a¡ecting ND1 labeling. Four moder-
ately potent complex I inhibitors (papaverine, capsai-
cin, 4-phenylpyridine and myxothiazol at 30^300
WM) give 42^66% labeling of PSST with normal
ND1 labeling. Of all the inhibitors, only myxothiazol
(30 WM) precipitated the ND1 subunit apparent by
streaking on SDS^PAGE with corresponding di¡u-
sion of the labeled 30 kDa region. Antimycin A and
amobarbital (a very weak complex I inhibitor) at the
concentrations used did not a¡ect either PSST or
ND1 labeling. Thus, these 15 respiratory inhibitors
have little or no e¡ect on ND1 labeling. However,
two compounds gave the very surprising result of
lowering PSST labeling to 35^49% while elevating
ND1 labeling to 175^200% of the control. MPP
and stigmatellin are therefore of special interest since
they simultaneously but oppositely a¡ect labeling of
the two subunits. Fig. 3 illustrates the marked di¡er-
ence in [3H]TDP labeling of PSST and ND1 in the
presence of rotenone and MPP, i.e. rotenone inhib-
its PSST labeling without e¡ect on ND1 while MPP
inhibits PSST and elevates ND1 labeling.
3.3. Correlation of MPP+-induced inhibition of
[3H]TDP labeling of PSST and NADH oxidase
activity
MPP at 0^20 or 30 mM preincubated with ETP
for 5 min inhibits PSST labeling and NADH oxidase
activity in a concentration-dependent manner (Fig.
4A). Inhibition of PSST labeling correlated well
with inhibition of NADH oxidase activity (with cor-
relation coe⁄cients of 0.92 and 0.84 at 8 nM and 80
nM [3H]TDP, respectively; data not shown). The
ion-pairing agent tetraphenylborate (TPB3) uncou-
ples inhibition of NADH oxidase activity by MPP
from its inhibition of labeling at PSST. Repetition of
the experiment shown in Fig. 4A in the presence of
TPB3 (10 WM) led to the expected strong increase in
the potency of MPP as an inhibitor of NADH oxi-
dase, i.e. enzymatic activity of complex I is fully
Table 1
E¡ects of respiratory chain inhibitors on NADH:quinone re-
ductase activity and on [3H]TDP labeling of PSST and ND1
Inhibitor (WM) Enzyme activity
IC50 (nM)
Labeling (%)
PSST ND1
No e¡ect on ND1 labeling
Pyridaben (2) 11 6 5 98
Rotenone (2) 12 6 5 96
Piericidin A (2) 25 6 5 93
Bullatacin (2) 2.9 6 5 93
Rolliniastatin I (2) 3.0 6 5 97
Fenpyroximate (2)* 1.2 6 5 72
Tebufenpyrad (2)* 180 6 5 88
Thiangazole (2)* 50 6 5 95
Fenazaquin (2)* 190 19 92
Papaverine (300)* 36 000 42 100
Capsaicin (300)* 86 000 46 96
4-Phenylpyridine (300)* 42 000 65 89
Myxothiazol (30) 3 000 66 110
Antimycin A (30) s 100 000 94 117
Amobarbital (3000)* 1.2 mM 107 95
Elevation of ND1 labeling
MPP (20 000) 0.9 mM 35 200
Stigmatellin (30) s 30 000 49 175
Enzyme activity IC50 values are for 5 min preincubation of en-
zyme and inhibitor before NADH:quinone reductase assay as
described in Section 2. For labeling, ETP (300 Wg protein in
3 ml sucrose-phosphate bu¡er pH 7.5) were treated sequentially
with the inhibitor, [3H]TDP (80 nM) and NADH (400 WM)
each for 10 min followed by SDS^PAGE analysis as in Fig.
3B. Labeling results are mean values from 2^5 experiments ex-
cept for single experiments indicated by an asterisk.
Fig. 2. E¡ects of cofactors on [3H]TDP labeling of PSST and
ND1. ETP (300 Wg protein) in sucrose-phosphate bu¡er pH 7.5
(3 ml) were labeled with [3H]TDP (80 nM) in the presence or
absence of the cofactors NAD or NADH (400 WM) and DB
(30 WM). DB showed no e¡ect on labeling of PSST and ND1
in controls or with NAD or NADH and was therefore not con-
sidered a variable in presenting this ¢gure or in the data analy-
sis. **Highly signi¢cant di¡erence (P6 0.01) compared with the
control (n = 4).
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blocked by 20 mM MPP in the presence of 10 WM
TPB3 (Fig. 4B) whereas, without the ion-pairing
agent, NADH oxidase activity is only reduced by
40% (Fig. 4A). However, the presence of TPB3 did
not a¡ect the degree of [3H]TDP displacement at
PSST by MPP (Fig. 4B).
3.4. E¡ects of MPP+ on [3H]TDP labeling of ND1
3.4.1. Heat instability con¢rms ND1 as the site of
MPP+-elevated [3H]TDP labeling of ETP
Heat denaturation (100‡C) of isolated complex I in
SDS^PAGE bu¡er leads to precipitation of the very
hydrophobic ND1 subunit [15]. This heat instability
was used to test whether the increase in [3H]TDP
binding at 30 kDa (the position of ND1) with 20
mM MPP was indeed at this complex I subunit.
Denaturation of labeled complex I (isolated by
Blue Native PAGE [16]) or labeled ETP in SDS sam-
ple bu¡er at 100‡C (4 min) resulted in 60% lower
recovery of the original radioactivity at the ND1
site than at the PSST site. This is consistent with
the MPP-elevated labeling being on the heat-sensi-
tive ND1.
Fig. 3. E¡ects of rotenone and MPP on [3H]TDP labeling of PSST and ND1. (A) Fluorogram illustrating labeling of PSST and
ND1 in untreated ETP (control), the inhibition of PSST but not ND1 labeling by rotenone, and the inhibition of PSST and elevation
of ND1 labeling by MPP. (B) Quantitation of gel slices corresponding to £uorogram. ETP (300 Wg protein) in sucrose-phosphate
bu¡er pH 7.5 (3 ml) were incubated for 30 min at 25‡C in bu¡er alone (control) or with rotenone (2 WM) or MPP (20 mM) then
photoa⁄nity labeled with [3H]TDP (80 nM) in the presence of NADH (400 WM). Each calibration bar at the bottom designates
1U106 dpm/mg protein; control values for labeling (pmol [3H]TDP/mg protein) are 12 þ 2 for PSST and 9.7 þ 3.4 for ND1 (n = 8).
Fig. 4. MPP-induced inhibition of [3H]TDP labeling of PSST and NADH oxidase activity. (A) Concentration-dependent inhibition
of labeling and enzymatic activity. ETP (100 Wg protein/ml) were incubated with MPP for 5 min at 25‡C and then labeled with
[3H]TDP (80 nM). Inhibition of enzymatic activity was determined in parallel experiments. (B) Experiment as in A but in the presence
of TPB3 (10 WM).
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3.4.2. Correlation of MPP+-induced elevation of ND1
labeling and decrease of PSST labeling
MPP increases [3H]TDP labeling of ND1 at 20
but not 2 mM (Fig. 5A) and in a time-dependent
manner (0^100 min) at 20 mM (Fig. 5B). This is a
highly reproducible observation since, at 20 mM
MPP with incubation times of 5^100 min, the pho-
toa⁄nity labeling is signi¢cantly increased by a fac-
tor of 1.9 þ 0.2 (n = 10; P6 0.005) compared to con-
trols without inhibitor (data not shown). The MPP-
induced decrease in PSST labeling is accompanied by
an increase in ND1 labeling (Fig. 5A,B). These stud-
ies, supplemented with additional experiments of the
same type, established a high correlation (r2 = 0.84)
between the decrease in PSST labeling and increase
in ND1 labeling (Fig. 5C).
3.5. E¡ects of stigmatellin on [3H]TDP labeling of
PSST and ND1
Stigmatellin, at concentrations below its IC50 value
for enzyme activity, was the only compound that
mimicked the action of MPP in three respects: par-
tial inhibition of NADH:oxidoreductase activity, de-
creased labeling of PSST and increased labeling of
ND1 (Table 1, Fig. 6). The decrease in labeling of
PSST coupled to an increase in labeling of ND1 is
dependent on stigmatellin concentration and attenu-
ated by omission of NADH from the incubation
(Fig. 6).
3.6. Common structural features for MPP+ and
stigmatellin
Stigmatellin, a semiquinone analogue, was com-
pared to ubisemiquinone and MPP by density func-
tional analysis of their electrostatic potential surfaces
using standard methods [14]. Although the calcula-
tions are not shown, the derived models indicate a
close structural similarity between stigmatellin and
the protonated ubisemiquinone radical with respect
Fig. 5. E¡ects of MPP concentration and incubation time on [3H]TDP labeling of PSST and ND1. (A) Concentration dependence.
ETP (100 Wg protein/ml) were incubated with MPP (0, 0.2, 2 or 20 mM) for 30 min at 25‡C and then photoa⁄nity labeled with
[3H]TDP (100 nM). (B) Time dependence. ETP (100 Wg protein/ml) were incubated with MPP (20 mM) for 10, 30, or 100 min at
25‡C followed by photoa⁄nity labeling with [3H]TDP (80 nM). (C) Elevation of ND1 labeling coupled to decrease of PSST labeling.
The data are from panels A and B, from Fig. 4 and supplemental experiments. Each data point represents a labeling experiment in
the presence of MPP relative to a control without MPP.
Fig. 6. E¡ects of stigmatellin on [3H]TDP labeling of ND1 and
PSST. ETP (100 Wg protein/ml) were labeled with [3H]TDP (80
nM) after incubation for 10 min at 25‡C with increasing con-
centrations of stigmatellin in the presence or absence of
NADH. (Left) Labeling of ND1. (Right) Labeling of PSST.
Conditions as in Table 1. Typical experiment shown with rela-
tionships con¢rmed in other studies.
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to similarly positioned centers at about 7 Aî distance
of highly positive and negative electrostatic potential
surfaces. Relative to MPP, the positive potential of
the polarized methyl group can be compared to the
phenolic hydroxyl substituent of stigmatellin and the
negative potential surface of the Z-electrons in the
phenyl ring then mimics the carbonyl oxygen of stig-
matellin with the 7 Aî distance maintained in all cases
(Fig. 1).
4. Discussion
4.1. [3H]TDP labels PSST and ND1
[3H]TDP photoa⁄nity labels only two proteins in
complex I with apparent molecular masses on SDS^
PAGE of 23 and 30 kDa, respectively. Labeling of
PSST is saturable, correlated with enzyme inhibition
and blocked by various structurally unrelated com-
plex I inhibitors. A common binding domain, with
partially overlapping sites for inhibitors of many
types, was also suggested earlier based on radioli-
gand binding [10,17^19] and £uorescence quenching
studies [19]. Labeling of ND1 does not saturate at
the [3H]TDP concentrations tested and is not dis-
placed with a number of inhibitors. Rotenone at
2 WM completely prevents [3H]TDP labeling at the
PSST site but does not measurably a¡ect photoa⁄n-
ity labeling of the ND1 subunit. While this suggests
that [3H]TDP labeling of ND1 is unspeci¢c it is in-
triguing to see that ND1, beside PSST, is the sole
protein labeled by [3H]TDP in ETP, which likely
consists of several hundred protein components.
Also, rotenone analogues used as photoa⁄nity
probes with isolated complex I have been shown to
label the ND1 site [15,20]. This suggests that both
PSST and ND1 have inhibitor binding sites but only
action at PSST directly blocks electron transport.
Here [3H]TDP is used to characterize the e¡ects on
complex I of various cofactors, substrates and inhib-
itors.
4.2. E¡ects of NADH and decylubiquinone on
[3H]TDP labeling
NADH (but not NAD) elevates [3H]TDP labeling
of PSST and lowers labeling of ND1, providing the
¢rst direct evidence for coupling between these two
subunits. With this ¢nding, NADH was routinely
added in the assays. NADH alters the pro¢le of tryp-
tic digestion in isolated complex I [21] and also
changes the cross-linking pattern with several re-
agents between various subunits in isolated complex
I [22]. NADH (but not NAD) changes the electron
paramagnetic resonance (EPR) signal of iron^sulfur
cluster N2 in submitochondrial particles [23] and ac-
tivates complex I from an inactive to an active state
[24]. These e¡ects were rationalized as NADH-in-
duced conformational changes of complex I possibly
linked to proton transfer reactions. Activated com-
plex I shows a higher a⁄nity to rotenone than deac-
tivated complex I and the transition from the active
to the deactivated state is very slow [24]. In the label-
ing experiments here, NADH is always oxidized to
NAD shortly before irradiation as it would quench
the UV light responsible for photoactivation of
[3H]TDP. The reported prolonged e¡ects of NADH
translate here in the altered [3H]TDP labeling of both
ND1 and PSST. DB (30 WM) does not a¡ect
[3H]TDP (80 nM) labeling suggesting that either
their binding sites do not overlap or that the binding
a⁄nity for this quinone is too low to e¡ectively com-
pete with the very potent [3H]TDP.
4.3. E¡ects of MPP+ on [3H]TDP labeling
MPP-induced parkinsonian syndrome is believed
to be related to binding at and inhibition of NAD-
H:ubiquinone oxidoreductase [7], leading to de-
creased ATP levels [25] and/or increased production
of reactive oxygen species [26,27]. MPP prevents
binding of [14C]rotenone to complex I [28]. It was
surprising to observe that MPP at 20 mM (but
not at 1 mM; see [4]) signi¢cantly increases [3H]TDP
labeling at ND1 while inhibiting PSST labeling. This
is in contrast to several other complex I inhibitors
which do not alter ND1 labeling. MPP-induced
inhibition of PSST labeling is concentration- and
time-dependent and correlates well with the degree
of NADH oxidase inhibition. The time dependence
may be related to the charged inhibitor slowly
penetrating into the membrane-bound enzyme com-
plex.
Catalytic amounts of the ion-pairing agent TPB3
strongly enhance the potency and kinetics of MPP
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as a complex I inhibitor perhaps by transporting the
ionic inhibitor through the lipid bilayer to a hydro-
phobic binding site [29]. However, TPB3 does not
a¡ect either the MPP-induced decrease in [3H]TDP
labeling of PSST or increase in labeling of ND1. This
apparent anomaly may be explained by two MPP-
speci¢c binding sites. Binding of MPP to the ¢rst,
more hydrophilic site a¡ects [3H]TDP labeling of
PSST and ND1. TPB3 is needed to shuttle MPP
to the second, more hydrophobic site. There, MPP
does not interfere with [3H]TDP binding, yet leads to
fast and complete block of enzymatic activity. Two
MPP binding sites were also suggested by kinetic
studies with MPP and its 4P-alkylated analogues
[30,31]. It should be stressed that the hydrophobic
MPP binding site does not appear to be shared
by the classical high-a⁄nity complex I inhibitors.
4.4. E¡ects of the semiquinone analogue stigmatellin
on [3H]TDP labeling
Stigmatellin is a moderately potent inhibitor of
NADH:Q1 reductase activity [8]. The action of
MPP at 20 mM was mimicked by stigmatellin at
30 WM with elevated ND1 labeling apparently
coupled to inhibition of PSST labeling. This suggests
a possible common mode of action. The opposite
e¡ects observed for NADH and stigmatellin on
[3H]TDP labeling indicate that they induce very dif-
ferent types of conformational changes. Stigmatellin
acts as a semiquinone analogue and potently inhibits
complex III at the Qo site [32]. It induces large con-
formational changes in both complex III [33] and the
eukaryotic photosynthetic b6f complex [34]. A com-
parison of the electrostatic potential surfaces indi-
cates that the seemingly unrelated MPP and stigma-
tellin (Fig. 1) ¢t remarkably well into a
pharmacophore of a protonated ubisemiquinone
structure. Some complex I inhibitors including 4P-al-
kyl-MPP analogues have been classi¢ed as semiqui-
none antagonists without direct evidence on their
binding sites [35]. Functional models of complex I
suggest more than one quinone binding site [36,37]
and there are two locally separated semiquinone spe-
cies observed by EPR in complex I of submitochon-
drial particles [38,39]. Labeling with [3H]TDP in the
presence and absence of TPB3 also suggests two
binding sites for MPP.
5. Conclusion
[3H]TDP, rotenone and a large number and great
variety of potent NADH:ubiquinone oxidoreductase
inhibitors bind to a single high-a⁄nity domain in the
PSST subunit, leading to a block in the mitochon-
drial electron transport chain. [3H]TDP also binds to
a low-a⁄nity site in ND1 not directly involved in
enzyme inhibition and not a¡ected by the majority
of complex I inhibitors in competitive binding stud-
ies. In contrast, the decreased labeling of PSST in the
presence of MPP is coupled to increased labeling of
ND1. This unique e¡ect of MPP is only shared by
the semiquinone analogue stigmatellin which may
suggest that, in contrast to all other inhibitors, these
two compounds act in a distinctly di¡erent way, pos-
sibly as semiquinone analogues at a common binding
site also situated ^ at least partially ^ in the PSST
subunit. Binding of these two compounds may lead
to allosteric modi¢cation observed as increased label-
ing of the ND1 subunit. This is the ¢rst direct ex-
perimental evidence that the PSST and ND1 subunits
work together in the coupling reaction between elec-
tron transfer and proton transfer. Perhaps, the com-
mon binding site for MPP and stigmatellin coin-
cides with the proposed ubiquinone binding site in
the PSST ^ 49 kDa subunit ^ ND1 region of the
catalytic core of complex I [40].
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